Insider Chart Past 6 Months
Technical Chart
Filings by transaction date
-
Feb 05, 2024 (filed on Feb 05, 2024)Insider Name:Shukla SathOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-45,093Price:$1.45
-
Feb 02, 2024 (filed on Feb 05, 2024)Insider Name:Keutzer TimothyOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-30,971Price:$1.36
-
Feb 02, 2024 (filed on Feb 05, 2024)Insider Name:Mahadevia AnkitOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-63,795Price:$1.37
-
Feb 02, 2024 (filed on Feb 05, 2024)Insider Name:Joseph Tamara LOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-30,906Price:$1.37
-
Feb 02, 2024 (filed on Feb 05, 2024)Insider Name:Hamed KamalOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-28,075Price:$1.37
-
Feb 02, 2024 (filed on Feb 05, 2024)Insider Name:Shukla SathOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-30,901Price:$1.37
-
Feb 01, 2024 (filed on Feb 05, 2024)Insider Name:Keutzer TimothyOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:239,731Price:--
-
Feb 01, 2024 (filed on Feb 05, 2024)Insider Name:Joseph Tamara LOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:239,731Price:--
-
Feb 01, 2024 (filed on Feb 05, 2024)Insider Name:Hamed KamalOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:239,731Price:--
-
Feb 01, 2024 (filed on Feb 05, 2024)Insider Name:Rajavelu EstherOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:119,866Price:--
Filings by filing date
-
Feb 02, 2024 (filed on Feb 05, 2024)Insider Name:Keutzer TimothyOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-30,971Price:$1.36
-
Feb 01, 2024 (filed on Feb 05, 2024)Insider Name:Keutzer TimothyOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:239,731Price:--
-
Feb 02, 2024 (filed on Feb 05, 2024)Insider Name:Mahadevia AnkitOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-63,795Price:$1.37
-
Feb 02, 2024 (filed on Feb 05, 2024)Insider Name:Joseph Tamara LOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-30,906Price:$1.37
-
Feb 01, 2024 (filed on Feb 05, 2024)Insider Name:Joseph Tamara LOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:239,731Price:--
-
Feb 02, 2024 (filed on Feb 05, 2024)Insider Name:Hamed KamalOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-28,075Price:$1.37
-
Feb 01, 2024 (filed on Feb 05, 2024)Insider Name:Hamed KamalOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:239,731Price:--
-
Feb 01, 2024 (filed on Feb 05, 2024)Insider Name:Rajavelu EstherOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:119,866Price:--
-
Feb 05, 2024 (filed on Feb 05, 2024)Insider Name:Shukla SathOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-45,093Price:$1.45
-
Feb 02, 2024 (filed on Feb 05, 2024)Insider Name:Shukla SathOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-30,901Price:$1.37
News
Biz Brief
Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 675 Massachusetts Ave Ste 14 CAMBRIDGE MA 02139-3309 |
Tel: | N/A |
Website: | https://sperotherapeutics.com |
IR: | See website |
Key People | ||
Satyavrat Shukla President, Chief Executive Officer, Director | Esther Rajavelu Chief Financial Officer and Chief Business Officer | Timothy Keutzer Chief Operating Officer | Kamal Hamed Chief Medical Officer |
Business Overview |
Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections with unmet need. Its lead product candidate, SPR720, is an oral antimicrobial agent in development for the treatment of nontuberculous mycobacterial (NTM) pulmonary disease, a rare orphan disease. Its partnership-directed programs consist of tebipenem HBr and SPR206. The tebipenem HBr is designed to be the oral carbapenem-class antibiotic for use to treat certain bacterial infections that cause complicated urinary tract infections (cUTIs), including pyelonephritis, caused by certain microorganisms, in adult patients who have limited oral treatment options. SPR206 is a direct acting intravenous (IV)-administered product candidate being developed as an option to treat MDR Gram-negative bacterial infections in the hospital setting. |
Financial Overview |
For the fiscal year ended 31 December 2023, Spero Therapeutics Inc revenues increased 94% to $103.8M. Net income totaled $22.8M vs. loss of $46.4M. Revenues reflect Grant revenue increase of 43% to $7M. Net Income reflects Restructuring decrease from $11.6M (expense) to $0K, Personnel related decrease of 41% to $11.1M (expense), Loss on extinguishment of liability rela decrease from $3.6M (expense) to $0K. |
Employees: | 46 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $2.85M as of Dec 31, 2023 |
Annual revenue (TTM): | $103.78M as of Dec 31, 2023 |
EBITDA (TTM): | $27.19M as of Dec 31, 2023 |
Net annual income (TTM): | $22.81M as of Dec 31, 2023 |
Free cash flow (TTM): | -$33.00M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 53,892,889 as of Apr 5, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |